Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol

Abstract

Patients with advanced-stage Burkitt lymphoma, including those with bone marrow and/or central nervous system involvement, can be cured with a short-term intensive chemotherapy regime tailored to the tumor burden.

Treatment Outcome of Adult Burkitt Lymphoma in Japanese Patients with Modified LMB Protocol : A Single Center Retrospective Analysis

“…This development appears to have improved the prognosis of adult BL. [3][4][5]8,10,14,15 The effectiveness of LMB protocol for adult BL was reported in 1995, 10 which was one of the earliest reports describing successful treatment of adult BL using HD-MTX. The original CODOX-M/IVAC was also reported by Magrath et al in 1996, 3 although this protocol was modified through clinical studies; 4,5 the reduction of MTX was among major changes because the principal cause of toxicity in the original CODOX-M/IVAC was the use of MTX at 6.7 g/m 2 in a single course.…”

“…1 (modified LMB protocol). [7][8][9][10] The doses of cyclophosphamide (CPA) in induction therapy, and cytrabine (AraC) and etoposide (VP-16) in consolidation #1 were reduced compared with those in the original LMB protocol. AraC in original consolidation #2 was also changed to VP-16 on days 3-6.…”

The role of hematopoietic SCT in adult Burkitt lymphoma

“…21 However, up to 90% and 80% of patients may have an elevated serum LDH and stage III-IV disease, respectively, and stratifying on the basis of these parameters may not allow sufficient discrimination between subsets of patients. 9,14,19,22,23 A recent Swedish population-based study derived a score based on age 440 years, performance status 41 and serum LDH 4upper limit of normal to be significant in predicting survival in multivariate analysis of 156 adult patients with BL treated between 2000 and 2010. Although such a score may serve as a useful tool in risk stratifying patients who have been treated with current regimes, further validation would be desirable, especially in the context of patients undergoing SCT.…”

“…10 Other regimes, such as the Hyper-CVAD, French LMB and Vanderbilt protocols, have achieved comparable response rates. [11][12][13][14][15] The incorporation of rituximab has been shown to further improve outcomes. 12,16,17 Furthermore, these results seem to be reproducible in HIV þ patients.…”

A Highly Therapy-Resistant Case of B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma Showing Strong BCL2 Staining, Otherwise Indistinguishable from Burkitt Lymphoma

“…After chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), a modified LMB regimen containing highdose methotrexate (MTX), cyclophosphamide, and cytarabine was performed. 6 Intrathecal chemotherapy (MTX 15 mg, cytarabine 40 mg, and prednisone 20 mg) was also performed 6 times because of the meningeal involvement. Multiple masses vanished and laboratory data were normalized when the protocol, divided into 3 phases containing 13 g/m 2 MTX in total, was completed as planned, and we judged the disease to be in complete remission because no lymphoma lesion was detected by positron emission tomography (Fig.…”